Mary Beth Humphrey

Dr. Mary Beth Humphrey


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
QPQisheng Peng
Qisheng Peng
SMShikha Malhotra
Shikha Malhotra
JTJames A. Torchia
James A. Torchia
WKWilliam G. Kerr
William G. Kerr
KCK. Mark Coggeshall
K. Mark Coggeshall
MHMary Beth Humphrey
Mary Beth Humphrey
The activation and fusion of macrophages and of osteoclasts require the adaptor molecule DNAX-activating protein of 12 kD (DAP12), which contains immunoreceptor tyrosine-based activation motifs (ITAMs). TREM2 (triggering receptor expressed on myeloid cells–2) is the main DAP12-associated receptor in osteoclasts and, similar to DAP12 deficiency, loss of TREM2 in humans leads to Nasu-Hakola disease, which is characterized by bone cysts and dementia. Furthermore, in vitro experiments have shown that deficiency in DAP12 or TREM2 leads to impaired osteoclast development and the formation of mononuclear osteoclasts. Here, we demonstrate that the ligation of TREM2 activated phosphatidylinositol 3-kinase (PI3K), extracellular signal–regulated kinase 1 (ERK1) and ERK2, and the guanine nucleotide exchange factor Vav3; induced the mobilization of intracellular calcium (Ca2+) and the reorganization of actin; and prevented apoptosis. The signaling adaptor molecule DAP10 played a key role in the TREM2- and DAP12-dependent recruitment of PI3K to the signaling complex. Src homology 2 (SH2) domain–containing inositol phosphatase-1 (SHIP1) inhibited TREM2- and DAP12-induced signaling by binding to DAP12 in an SH2 domain–dependent manner and preventing the recruitment of PI3K to DAP12. These results demonstrate a previously uncharacterized interaction of SHIP1 with DAP12 that functionally limits TREM2- and DAP12-dependent signaling and identify a mechanism through which SHIP1 regulates key ITAM-containing receptors by directly blocking the binding and activation of PI3K.

1 July 2009 in The American Journal of Medicine
Verified
Journal Article
Closed access
TATauseef Ali
Tauseef Ali
DLDavid Lam
David Lam
MBMichael S. Bronze
Michael S. Bronze
MHMary Beth Humphrey
Mary Beth Humphrey

11 August 2014 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Closed access
KPKeshav Panday
Keshav Panday
AGAmitha Gona
Amitha Gona
MHMary Beth Humphrey
Mary Beth Humphrey
Drug-induced osteoporosis is a significant health problem and many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. In addition to glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, thiazolidinediones, anticonvulsants, medroxyprogesterone acetate, aromatase inhibitors, androgen deprivation therapy, heparin, calcineurin inhibitors, and some chemotherapies have deleterious effects on bone health. Furthermore, many patients are treated with combinations of these medications, possibly compounding the harmful effects of these drugs. Increasing physician awareness of these side effects will allow for monitoring of bone health and therapeutic interventions to prevent or treat drug-induced osteoporosis.

2 November 2017 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
ELErika Barboza Prado Lopes
Erika Barboza Prado Lopes
AFAdrian Filiberti
Adrian Filiberti
SHSyed Ali Husain
Syed Ali Husain
MHMary Beth Humphrey
Mary Beth Humphrey

1 February 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SSStavros Stavrakis
Stavros Stavrakis
KEKhaled Elkholey
Khaled Elkholey
LMLynsie Morris
Lynsie Morris
MNMonika Niewiadomska
Monika Niewiadomska
ZAZain Ul Abideen Asad
Zain Ul Abideen Asad
MHMary Beth Humphrey
Mary Beth Humphrey
Background: A systemic proinflammatory state plays a central role in the development of heart failure with preserved ejection fraction. Low‐level transcutaneous vagus nerve stimulation suppresses inflammation in humans. We conducted a sham‐controlled, double‐blind, randomized clinical trial to examine the effect of chronic low‐level transcutaneous vagus nerve stimulation on cardiac function, exercise capacity, and inflammation in patients with heart failure with preserved ejection fraction. Methods and Results: Patients with heart failure with preserved ejection fraction and at least 2 additional comorbidities (obesity, diabetes, hypertension, or age ≥65 years) were randomized to either active (tragus) or sham (earlobe) low‐level transcutaneous vagus nerve stimulation (20 Hz, 1 mA below discomfort threshold), for 1 hour daily for 3 months. Echocardiography, 6‐minute walk test, quality of life, and serum cytokines were assessed at baseline and 3 months. Fifty‐two patients (mean age 70.4±9.2 years; 70% female) were included (active, n=26; sham, n=26). Baseline characteristics were balanced between the 2 arms. Adherence to the protocol of daily stimulation was >90% in both arms ( P >0.05). While the early mitral inflow Doppler velocity to the early diastolic mitral annulus velocity ratio did not differ between groups, global longitudinal strain and tumor necrosis factor‐α levels at 3 months were significantly improved in the active compared with the sham arm (−18.6%±2.5% versus −16.0%±2.4%, P =0.002; 8.9±2.8 pg/mL versus 11.3±2.9 pg/mL, P =0.007, respectively). The reduction in tumor necrosis factor‐α levels correlated with global longitudinal strain improvement (r=−0.73, P =0.001). Quality of life was better in the active arm. No device‐related side effects were observed. Conclusions: Neuromodulation with low‐level transcutaneous vagus nerve stimulation over 3 months resulted in a significant improvement in global longitudinal strain, inflammatory cytokines, and quality of life in patients with heart failure with preserved ejection fraction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03327649.

17 July 2017 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
EKEvangelia Kalaitzoglou
Evangelia Kalaitzoglou
TGTimothy M. Griffin
Timothy M. Griffin
MHMary Beth Humphrey
Mary Beth Humphrey